Article Impact Level: HIGH Data Quality: STRONG Summary of Leukemia https://doi.org/10.1038/s41375-026-03152-5 Dr. Sophie Steinhäuser et al.
Points
- Researchers investigated how IDH1 and DNMT3A epigenetic mutations influence the three dimensional spatial organization of DNA and gene transcription across acute myeloid leukemia patient samples and cellular models.
- Chromatin conformation capture and RNA sequencing analyses identified thousands of shared and distinct DNA loop alterations that directly correlated with global transcriptional changes and altered leukemic signaling pathways.
- In IDH1 mutated acute myeloid leukemia samples the investigators discovered loop mediated upregulation of the IGF1R gene which conferred heightened cellular sensitivity to the targeted inhibitor BMS seven five four eight zero seven.
- Combination treatment experiments demonstrated that co administering the IGF1R inhibitor with the established clinical IDH1 inhibitor ivosidenib produced synergistic therapeutic efficacy in mutant cellular models.
- Authors concluded that mapping global three dimensional structural DNA alterations provides a robust foundational framework for developing novel precision therapies addressing resistant acute myeloid leukemia entities.
Summary
This study evaluated genome-wide three-dimensional DNA conformational changes associated with IDH1 and DNMT3A mutations in acute myeloid leukemia (AML) to identify mutation-specific leukemic signaling pathways and therapeutic vulnerabilities. Published in Leukemia by researchers co-led by Prof. Claudia Baldus and Prof. Malte Spielmann, the investigation addressed how epigenetic regulator mutations disrupt spatial genome organization. Given that IDH1 and DNMT3A mutations alter DNA methylation patterns, the research sought to determine whether aberrant methylation at CTCF-binding sites disrupts DNA-loop formation, thereby driving transcriptional dysregulation and therapeutic resistance in AML.
Using cellular models expressing IDH1 p.R132H or DNMT3A p.R882H mutations alongside primary AML patient samples, the investigators analyzed mutation-specific 3D-DNA architecture via chromatin-conformation-capture (HiC) and transcriptional profiles via RNA sequencing. The analyses revealed thousands of shared and distinct alterations in genomic compartmentalization and DNA-loop formation for both mutant entities, establishing that 3D-genome architecture broadly modulates gene expression. Specifically, loop-mediated transcriptional upregulation of the IGF1R gene in IDH1-mutated AML correlated with heightened cellular sensitivity to the IGF1R inhibitor BMS-754807, exhibiting synergistic efficacy when combined with the clinical IDH1 inhibitor ivosidenib. Conversely, DNMT3A-mutated AML models demonstrated specific therapeutic sensitivity to the p38/MAPK inhibitor ralimetinib.
The authors conclude that IDH1 and DNMT3A mutations drive global, mutation-specific reorganizations of three-dimensional DNA architecture that govern aberrant transcriptional activity in AML. By establishing a comprehensive genomic map linking 3D-loop alterations to altered signaling pathways, these findings uncover novel targeted therapeutic vulnerabilities and combination strategies to overcome drug resistance in high-risk mutant AML subtypes.
Link to the article: https://www.nature.com/articles/s41375-026-03152-5
References
Steinhäuser, S., Sreenivasan, V. K. A., Baden, D., Denker, M., Beder, T., Richter, K., Hutter, T., Steer, B., Yumiceba, V., Schultz, K., Hartmann, A. M., Wolgast, N., Lipinski, S., Bastian, L., Bendig, S., Brüggemann, M., Fransecky, L., Neumann, M., Silva, P., … Baldus, C. D. (2026). Alterations in 3D-DNA architecture drive unique leukemic profiles in IDH1- and DNMT3A-mutant acute myeloid leukemia. Leukemia, 1–10. https://doi.org/10.1038/s41375-026-03152-5
